Vinorel 10 mg/ml (Injection)
50 mg vial: ৳ 7,800.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Vinorelbine tartrate |
| Company | Beacon pharmaceuticals plc |
Indications
- Treatment of non-small cell lung cancer in combination with cisplatin
- Treatment of metastatic non-small cell lung cancer as a single agent
Pharmacology
- Binds to tubulin
- Inhibits microtubule formation
- Arrests cell at metaphase
Dosage & Administration
- Intravenous dosage for cervical cancer: 30 mg/m2 on days 1 and 8 of a 21-day cycle
- Intravenous dosage for breast and ovarian cancer: 25 mg/m2 once every 7 days
- Intravenous dosage for non-small cell lung cancer as single agent: 30 mg/m2 weekly
- Intravenous dosage for non-small cell lung cancer in combination therapy with cisplatin: 25-30 mg/m2 every 7 days
- Oral dosage for non-small cell lung cancer: 60 mg/m2 once weekly, may increase to 80 mg/m2
- Monitoring of neutrophil count prior to administration of subsequent doses
- Requirement of normal saline flushing after each administration
- Guidelines for dose adjustment in hepatic impairment
Interaction
- Increased risk of granulocytopenia with cisplatin
- Increased risk of neurotoxicity with paclitaxel, itraconazole, ketoconazole
- Increased radiosensitizing effects with radiation therapy
- Increased pulmonary toxicity with mitomycin
- Increased myelotoxicity with zidovudine
- Possible interaction with CYP3A inhibitors
- Potential increase in vincristine levels with aprepitant
- Risk of infection with live vaccines
Contraindications
- Hypersensitivity to vinorelbine or other vinca alkaloids
- Severe current or recent infection
- Neutropenia
- Thrombocytopenia
- Severe hepatic impairment
- Pregnancy
- Lactation
Side Effects
- Neurotoxicity
- Peripheral paraesthesia
- Abdominal pain
- Severe constipation
- Diarrhea
- Alopecia
- Dose limiting granulocytopenia, leukopenia, and anemia
- Intestinal obstruction
- Nausea
- Local pain and thrombophlebitis with injection
Pregnancy & Lactation
- Category D - positive evidence of human fetal risk
- Benefits may outweigh the risks in specific situations
Precautions & Warnings
- Hepatic impairment
- Compromised bone marrow reserve
- History or pre-existing neuropathy
- Monitoring of CBC with differentials
- Guidelines for extravasation management
- Recommendations for contraception during and after treatment
- Instructions for oral administration
Use in Special Populations
- Dose adjustments in hepatic impairment
- Special considerations for massive liver metastases
Therapeutic Class
- Cytotoxic Chemotherapy
Storage Conditions
- Intravenous: Store at 2-8°C, protect from light
- Oral: Store at 2-8°C